Effects of antidepressants on plasma metabolites of nitric oxide in major depressive disorder: Comparison between milnacipran and paroxetine

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 33, Issue 8, 2009, Pages 1451-1453

  Ikenouchi Sugita, Atsuko ^a   Yoshimura, Reiji ^a   Hori, Hikaru ^a   Umene Nakano, Wakako ^a   Ueda, Nobuhisa ^a   Nakamura, Jun ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Depression; Milnacipran; Nitric oxide; Paroxetine

Indexed keywords

MILNACIPRAN; NITRIC OXIDE; PAROXETINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE COURSE; DRUG DOSE INCREASE; DRUG EFFECT; FEMALE; HUMAN; MAJOR DEPRESSION; MALE; METABOLITE; OUTPATIENT; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ADULT; AGED; ANTIDEPRESSIVE AGENTS; BLOOD PLATELETS; CASE-CONTROL STUDIES; CYCLOPROPANES; DEPRESSIVE DISORDER, MAJOR; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NITRIC OXIDE; PAROXETINE; STATISTICS AS TOPIC; TIME FACTORS;

EID: 71549161718     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2009.07.028     Document Type: Article

References (23)

1. Archer S.L. Measurement of nitric oxide in biological models. FASEB J 7 (1993) 349-360
2. Carney R.M., Freedland K.E., Miller G.E., and Jaffe A.S. Depression as a risk factor for cardiac mortality and morbidity: a review of potential mechanisms. J Psychosom Res 53 (2002) 897-902
3. Chrapko W.E., Jurasz P., Radomski M.W., Lara N., Archer S.L., and Le Melledo J.M. Decreased platelet nitric oxide synthase activity and plasma nitric metabolites in major depressive disorder. Biol Psychiatry 56 (2004) 129-134
4. Chrapko W.E., Jurasz P., Radomski M.W., Archer S.L., Newman S.C., Baker G., et al. Alteration of decreased plasma NO metabolites and platelet NO synthase activity by paroxetine in depressed patients. Neuropsychopharmacol 31 (2006) 1286-1293
5. Chrapko W.E., Jurasz P., Radomski M.W., Lara N., Archer S.L., and Le Melledo J.M. Decreased platelet nitric oxide synthase activity and plasma nitric metabolites in major depressive disorder. Biol Psychiatry 56 (2004) 129-134
6. Costa M.A., Elesgaray R., Loria A., Balaszczuk A.M., and Arranz C. Vascular and renal effects of dopamine during extracellular volume expansion: role of nitric oxide pathway. Life Sci 78 (2006) 1543-1549
7. Finkel M.S., Laghrissi-Thode F., Pollock B.G., and Rong J. Paroxetine is a novel nitric oxide synthase inhibitor. Psychopharmacol Bull 32 (1996) 653-658
8. First M.B., Spitzer R.L., Gibbon M., and Williams J.B.W. The Structured Clinical Interview for DSM-III-R personality disorders (SCID-II, version 2.0): part I: description. J Pers Disord 9 (1995) 83-91
9. Kim Y.K., Paik J.W., Lee S.W., Yoon D., Han C., and Lee B.H. Increased plasma nitric oxide level associated with suicide attempt in depressive patients. Prog Neuropsychopharmacol Biol Psychiatry 30 (2006) 1091-1096
10. Lara N., Archer S.L., Backer G.B., and Le Melledo J.M. Paroxetine-induced increase in metabolic end products of nitric oxide (NO). J Clin Psychopharmacol 23 (2003) 641-645
11. Lee B.H., Lee S.W., Yoon D., et al. Increased plasma nitric oxide metabolites in suicide attempters. Neuropsychobiol 53 (2006) 127-132
12. Radomski M.W., Palmer R.M.J., and Moncada S. The antiaggregation properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br J Pharmacol 92 (1987) 639-646
13. Radomski M.W., Palmer R.M.J., and Moncada S. An l-arginine/nitric oxide pathway present in human platelets aggregation. Proc Natl Acad Sci USA 87 (1990) 1788-1792
14. Rajagopalan S., Brook R., Rubenfire M., Pitt E., Young E., and Pitt B. Abnormal brachial artery flow-mediated vasolidation in young adults with major depression. Am J Cardiol 88 (2001) 196-198
15. Roger K.M., Bonar C.A., Estrella J.L., and Yang S. Inhibitory effect of glucocorticoid on coronary artery endothelial function. Am J Physiol Heart Circ Physiol 27 (2002) 1922-1928
16. Shinkai K., Yoshimura R., Ueda N., Okamoto K., and Nakamura J. Associations between baseline plasma MHPG (3-methoxy-4-hydroxyphenylglycol) levels and clinical responses with respect to milnacipran versus paroxetine treatment. J Clin Psychopharmacol; 24 (2004) 11-17
17. Suzuki E., Yagi G., Nakaki T., Kanba S., and Asai M. Elevated plasma nitrate levels in depressive states. J Affect Disord 63 1-3 (2001) 221-224
18. Suzuki E., Nakaki T., Nakamura M., and Miyaoka H. Plasma nitrate levels in deficit versus non-deficit forms of schizophrenia. Rev Psychiatr Neurosci 28 (2003) 288-292
19. Suzuki E., Yoshida Y., Shibuya A., and Miyaoka H. Nitric oxide involvement in depression during interferon-alpha therapy. Int J Neuropsychopharmacol 6 (2003) 415-419
20. Ueda N., Yoshimura R., Shinkai K., and Nakamura J. Plasma levels of catecholamine metabolites predict the response to sulpiride or fluvoxamine in major depression. Pharmacopsychiatry 35 (2002) 175-181
21. Umene-Nakano W, Yoshimura R, Ueda N, Suzuki A, Ikenouchi-Sugita A, Hori H, et al., in press. Predictive factors for responding sertraline treatment: views from dynamics of plasma catecholamine metabolites and serotonin transporter polymorphism. J Psychopharmacol.
22. Wallerath T., Witte K., Schafer S.C., et al. Down-regulation of the expression of endothelial NO synthase is likely to contribute to glucocorticoid-mediated hypertension. Proc Natl Acad Sci USA 96 (1999) 13357-13362
23. Yoshimura R., Nakamura J., Shinkai K., and Ueda N. Clinical response to antidepressants treatment and 3-methoxy-4-hydroxyphenylgly levels: mini review. Prog Neuropsychopharmacol Biol Psychiatry 28 (2004) 611-616